Sarcoma With EWSR1/FUS : POU2AF3 (COLCA2) Fusion : Molecular and Clinicopathologic Characterization of a Case Series. (COL'CHIC)
Sarcomas with the EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript represent a new molecularly defined entity, first described in 2023 (1). There are 24 cases reported in the literature, including 3 descriptive series totaling 19 cases (1-3). Clinically, this is an aggressive entity affecting patients of varying ages (16-74 years), most commonly located in the sinonasal tract, and capable of involving both bone and soft tissue. A few extrasinonasal cases have also been reported. Histologically, two morphological groups have been described (3): the first group (the rarest) is characterized by a low-grade morphology with non-atypical spindle cells; the second group is morphologically high-grade, featuring spindle, round, or epithelioid cells and possible divergent differentiation (epithelial, neuroendocrine, striated muscle, or bone).
The immunophenotype of these lesions is nonspecific, with variable positivity for various markers such as S100, CD99, AE1/3, CD56, chromogranin, synaptophysin, SATB2, CD117, GFAP, and EMA.
Given the clinical, morphological, and immunohistochemical features of this entity, numerous differential diagnoses can be considered: synovial sarcoma, malignant tumor of the peripheral nerve sheaths, Ewing sarcoma, myoepithelial tumor, biphenotypic sinonasal sarcoma, etc.
研究概览
研究类型
注册 (估计的)
联系人和位置
学习联系方式
- 姓名:WEINGERTNER Noëlle, MD
- 电话号码:+33388128241
- 邮箱:noelle.weingertner@chru-strasbourg.fr
参与标准
资格标准
适合学习的年龄
接受健康志愿者
有资格学习的性别
取样方法
研究人群
sarcomas
描述
Inclusion Criteria:
- Patient whose test results indicated "the presence of a fusion transcript involving the POU2AF3 gene (formerly COLCA2)"
- Adult patient
- Who has consented to the reuse of their samples for scientific and medical research related to their condition or related conditions
Exclusion Criteria:
-
学习计划
研究是如何设计的?
设计细节
- 观测模型:COHORT
- 时间观点:RETROSPECTIVE
队列和干预
团体/队列 |
干预/治疗 |
|---|---|
|
SARCOMA
Sarcomas exhibiting an EWSR1/FUS :: POU2AF3 (COLCA2) fusion transcript |
methylation profiling |
研究衡量的是什么?
主要结果指标
结果测量 |
措施说明 |
大体时间 |
|---|---|---|
|
Clustering Common to methylation analysis and RNA-seq.
大体时间:11 months
|
Determine whether sarcomas with the EWSR1/FUS :: POU2AF3 fusion transcript constitute a distinct entity |
11 months
|
合作者和调查者
研究记录日期
研究主要日期
学习开始 (估计的)
初级完成 (估计的)
研究完成 (估计的)
研究注册日期
首次提交
首先提交符合 QC 标准的
首次发布 (实际的)
研究记录更新
最后更新发布 (实际的)
上次提交的符合 QC 标准的更新
最后验证
更多信息
与本研究相关的术语
其他相关的 MeSH 术语
其他研究编号
- RC26_0488
计划个人参与者数据 (IPD)
计划共享个人参与者数据 (IPD)?
药物和器械信息、研究文件
研究美国 FDA 监管的药品
研究美国 FDA 监管的设备产品
此信息直接从 clinicaltrials.gov 网站检索,没有任何更改。如果您有任何更改、删除或更新研究详细信息的请求,请联系 register@clinicaltrials.gov. clinicaltrials.gov 上实施更改,我们的网站上也会自动更新.